The University of Chicago Header Logo

Samuel Hellman

Concepts (303)

Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.


Name Number of Publications Most Recent Publication Publications by All Authors Concept Score Why?
Breast Neoplasms
26
2015
2831
1.510
Why?
Neoplasms
21
2023
2794
1.400
Why?
Neoplasm Metastasis
19
2016
1049
1.170
Why?
Prostatic Neoplasms
9
2007
1592
0.770
Why?
Radiotherapy
6
2014
326
0.740
Why?
Epigenesis, Genetic
1
2023
447
0.720
Why?
Antineoplastic Agents
8
2015
2324
0.530
Why?
Knowledge
1
2014
29
0.520
Why?
Neovascularization, Pathologic
6
2004
338
0.500
Why?
Education, Medical
2
2014
229
0.490
Why?
Models, Theoretical
3
2005
482
0.470
Why?
Physicians, Primary Care
1
2014
103
0.460
Why?
Humans
72
2023
83873
0.440
Why?
Randomized Controlled Trials as Topic
5
2004
825
0.440
Why?
Lymphatic Metastasis
8
2003
479
0.440
Why?
Physician-Patient Relations
4
2007
602
0.420
Why?
Radiation, Ionizing
4
2010
120
0.400
Why?
Radiation Oncology
3
1997
124
0.380
Why?
Human Experimentation
1
2010
39
0.370
Why?
Nucleoside-Diphosphate Kinase
2
2000
11
0.360
Why?
Ethics, Research
1
2010
52
0.360
Why?
Monomeric GTP-Binding Proteins
2
2000
18
0.360
Why?
Disease-Free Survival
12
2011
1203
0.360
Why?
Patient Advocacy
3
2015
49
0.350
Why?
MicroRNAs
4
2015
523
0.340
Why?
Chemotherapy, Adjuvant
8
2005
461
0.330
Why?
Genetic Therapy
9
2008
340
0.330
Why?
Physician's Role
4
2005
179
0.320
Why?
Models, Economic
1
2007
60
0.310
Why?
Hematopoiesis
1
2008
164
0.310
Why?
Neoplasm Recurrence, Local
5
2005
1257
0.300
Why?
Liver Neoplasms
3
2018
680
0.300
Why?
Neoplastic Stem Cells
1
2008
142
0.290
Why?
Prostatectomy
3
2007
443
0.290
Why?
Decision Making
3
2007
631
0.290
Why?
Tumor Necrosis Factor-alpha
7
2008
673
0.290
Why?
Androgen Antagonists
2
2005
137
0.280
Why?
Hematopoietic Stem Cells
1
2008
292
0.280
Why?
Prognosis
11
2005
3618
0.280
Why?
Transcription Factors
6
2004
1492
0.280
Why?
Attitude of Health Personnel
2
2005
633
0.270
Why?
Colorectal Neoplasms
3
2018
911
0.270
Why?
Antineoplastic Agents, Hormonal
2
2003
148
0.270
Why?
Prostate-Specific Antigen
2
1998
328
0.270
Why?
Ethics, Medical
3
2000
302
0.260
Why?
Attitude to Health
1
2005
220
0.250
Why?
Nitriles
1
2004
143
0.240
Why?
Triazoles
1
2004
96
0.240
Why?
Biomedical Research
3
2014
366
0.240
Why?
Epithelial-Mesenchymal Transition
1
2023
68
0.240
Why?
History, 20th Century
3
2010
312
0.230
Why?
Sentinel Lymph Node Biopsy
1
2003
59
0.230
Why?
Managed Care Programs
2
2000
42
0.220
Why?
Brachytherapy
1
2003
121
0.220
Why?
Melanoma
2
2013
443
0.210
Why?
Proliferating Cell Nuclear Antigen
2
2000
65
0.210
Why?
Disease Progression
8
2012
1478
0.210
Why?
Lymph Nodes
4
2000
527
0.210
Why?
Lymph Node Excision
1
2003
208
0.200
Why?
Aged
16
2018
18098
0.200
Why?
Biomarkers, Tumor
3
2003
1441
0.200
Why?
Medical Oncology
2
2014
347
0.200
Why?
Female
31
2018
43741
0.190
Why?
Carcinoma
1
2003
427
0.190
Why?
Survival Analysis
6
2013
1531
0.190
Why?
Combined Modality Therapy
9
2005
1645
0.190
Why?
Skin Neoplasms
1
2004
524
0.180
Why?
Clinical Trials as Topic
4
2014
1155
0.180
Why?
Cadherins
1
2000
149
0.180
Why?
Middle Aged
16
2018
24691
0.180
Why?
Radiosurgery
2
2013
272
0.170
Why?
Mammography
2
2000
457
0.170
Why?
Radiotherapy, Adjuvant
4
2005
291
0.160
Why?
Gene Amplification
1
2018
131
0.160
Why?
History, 21st Century
2
2009
175
0.150
Why?
Immediate-Early Proteins
4
2004
164
0.150
Why?
Mastectomy
2
2004
231
0.150
Why?
Quality of Health Care
1
2000
375
0.150
Why?
Antigens, Neoplasm
1
1998
319
0.150
Why?
Prescription Fees
1
2015
10
0.140
Why?
Disease Models, Animal
4
2016
2186
0.140
Why?
Insurance Coverage
1
1996
107
0.140
Why?
Consumer Advocacy
1
1995
10
0.140
Why?
United States
7
2015
6425
0.140
Why?
Health Care Rationing
1
1996
79
0.140
Why?
Microcirculation
3
2000
103
0.140
Why?
Aged, 80 and over
7
2018
6453
0.130
Why?
Chromosomes, Human, Pair 14
1
2015
49
0.130
Why?
Drug Costs
1
2015
61
0.130
Why?
Erectile Dysfunction
2
2007
69
0.130
Why?
Neoplasm Staging
5
2004
1932
0.130
Why?
Patients
1
1995
98
0.130
Why?
Medical Laboratory Science
1
1994
7
0.130
Why?
Radiotherapy, Computer-Assisted
2
2008
25
0.130
Why?
Clinical Medicine
1
1994
34
0.120
Why?
Aging
1
1998
670
0.120
Why?
Life Expectancy
1
1994
82
0.120
Why?
Genetic Engineering
1
1994
112
0.120
Why?
Urinary Incontinence
2
2007
192
0.120
Why?
Patient Participation
1
2015
207
0.120
Why?
Male
13
2018
40239
0.120
Why?
Adult
12
2018
25203
0.110
Why?
History, 19th Century
2
2009
59
0.110
Why?
Health Care Reform
1
1994
90
0.110
Why?
Data Interpretation, Statistical
2
2004
296
0.110
Why?
Treatment Outcome
6
2013
7776
0.110
Why?
Diagnostic Imaging
1
2015
455
0.100
Why?
Evidence-Based Medicine
2
2005
422
0.100
Why?
Animals
15
2016
26005
0.100
Why?
Informed Consent
2
2010
259
0.100
Why?
Neoplasm Transplantation
6
2016
386
0.100
Why?
Age Factors
3
2007
1823
0.100
Why?
Philosophy, Medical
2
2005
17
0.100
Why?
Follow-Up Studies
4
2000
3603
0.100
Why?
Multivariate Analysis
3
1998
988
0.100
Why?
Ohio
1
2010
36
0.100
Why?
Tamoxifen
2
2004
165
0.090
Why?
Hodgkin Disease
1
1991
173
0.090
Why?
NM23 Nucleoside Diphosphate Kinases
2
2000
5
0.090
Why?
Lung
2
2012
1124
0.090
Why?
Biological Evolution
1
1997
901
0.090
Why?
Research Subjects
1
2010
73
0.090
Why?
X-Ray Therapy
1
2008
6
0.090
Why?
Universities
1
2010
135
0.090
Why?
Cell Line, Tumor
5
2015
2380
0.090
Why?
Lung Neoplasms
3
2013
2221
0.090
Why?
Analysis of Variance
2
2004
914
0.090
Why?
Military Personnel
1
2010
79
0.090
Why?
Adenocarcinoma
3
2012
1155
0.080
Why?
Radiation-Sensitizing Agents
1
2008
96
0.080
Why?
Survival Rate
3
2012
1843
0.080
Why?
Melanoma, Experimental
1
2008
101
0.080
Why?
Philosophy
1
2007
9
0.080
Why?
Radiotherapy, Conformal
1
2008
88
0.080
Why?
Urethral Stricture
1
2007
11
0.080
Why?
Rectal Diseases
1
2007
29
0.080
Why?
Critical Pathways
1
2007
35
0.080
Why?
Practice Patterns, Physicians'
1
1993
573
0.080
Why?
DNA-Binding Proteins
4
2004
1201
0.080
Why?
Mutation
1
2018
3889
0.080
Why?
Actuarial Analysis
2
1997
66
0.070
Why?
Phenotype
3
2015
2323
0.070
Why?
Time Factors
4
2005
5176
0.070
Why?
Fund Raising
1
2005
2
0.070
Why?
Academies and Institutes
1
2006
30
0.070
Why?
Predictive Value of Tests
3
2003
1636
0.070
Why?
Dermatology
1
2006
35
0.070
Why?
Gene Expression Regulation
3
2002
1889
0.070
Why?
Immunohistochemistry
3
2000
1736
0.070
Why?
Gene Expression Profiling
3
2018
1355
0.070
Why?
Trastuzumab
1
2005
64
0.070
Why?
Heterografts
2
2015
98
0.070
Why?
Sample Size
1
2005
128
0.070
Why?
Mastectomy, Radical
2
1995
10
0.060
Why?
Drug Administration Schedule
2
2003
917
0.060
Why?
Patient Satisfaction
1
2007
457
0.060
Why?
Antibiotics, Antineoplastic
1
2004
109
0.060
Why?
Databases, Factual
1
2007
792
0.060
Why?
Doxorubicin
1
2004
284
0.060
Why?
Radiation Dosage
2
2011
223
0.060
Why?
Antineoplastic Combined Chemotherapy Protocols
3
2004
2390
0.060
Why?
Carcinoma, Lewis Lung
2
2000
22
0.060
Why?
Mice
9
2015
10930
0.060
Why?
Neoplasm Invasiveness
1
2004
522
0.060
Why?
Cell Transformation, Neoplastic
1
2005
412
0.060
Why?
Interdisciplinary Communication
1
2003
127
0.050
Why?
Surgical Procedures, Operative
1
2004
184
0.050
Why?
Early Growth Response Protein 1
4
2004
54
0.050
Why?
Kaplan-Meier Estimate
2
2018
854
0.050
Why?
Lymphedema
1
2003
75
0.050
Why?
Transcriptional Activation
1
2002
276
0.050
Why?
Sensitivity and Specificity
2
2003
1967
0.050
Why?
Coumarins
1
2000
13
0.050
Why?
Risk
1
2003
671
0.050
Why?
Dose-Response Relationship, Radiation
2
2000
189
0.050
Why?
Oligonucleotide Array Sequence Analysis
1
2003
682
0.050
Why?
Immunity, Cellular
1
2001
175
0.050
Why?
Risk Assessment
2
2005
2223
0.050
Why?
Tumor Cells, Cultured
5
2002
1030
0.050
Why?
Gene Expression
2
2015
1276
0.050
Why?
Cisplatin
1
2002
600
0.050
Why?
Databases as Topic
1
2000
92
0.050
Why?
Mice, Nude
5
2002
762
0.050
Why?
Cancer Vaccines
1
2001
154
0.050
Why?
Antibodies, Monoclonal, Humanized
1
2005
918
0.050
Why?
Carcinoma, Lobular
1
2000
79
0.040
Why?
Antibodies, Monoclonal
1
2005
1357
0.040
Why?
Plasminogen
1
1998
41
0.040
Why?
Apoptosis
3
2008
1667
0.040
Why?
Genetic Vectors
4
2004
434
0.040
Why?
Class II Phosphatidylinositol 3-Kinases
1
2018
8
0.040
Why?
Carcinoma, Ductal, Breast
1
2000
154
0.040
Why?
Research
2
2003
252
0.040
Why?
Receptor, Notch1
1
2018
83
0.040
Why?
Transcription, Genetic
1
2002
1118
0.040
Why?
Paraffin Embedding
1
1997
78
0.040
Why?
Severity of Illness Index
1
2003
1753
0.040
Why?
Xenograft Model Antitumor Assays
2
2011
448
0.040
Why?
Mutagenesis
1
1997
199
0.040
Why?
Adrenalectomy
1
1996
41
0.040
Why?
Axilla
1
1997
93
0.040
Why?
Insurance, Health
1
1998
148
0.040
Why?
Ovariectomy
1
1996
78
0.040
Why?
Neoplasm Proteins
1
2000
533
0.040
Why?
Peptide Fragments
1
1998
458
0.040
Why?
HCT116 Cells
1
2016
149
0.040
Why?
Vascular Endothelial Growth Factor A
1
2018
387
0.040
Why?
Researcher-Subject Relations
1
1996
4
0.040
Why?
Molecular Biology
1
1996
88
0.040
Why?
Immunotherapy
1
2001
595
0.040
Why?
Carcinoma, Non-Small-Cell Lung
1
2004
1055
0.040
Why?
Social Responsibility
1
1996
57
0.030
Why?
Fibrosarcoma
1
1995
86
0.030
Why?
Luminescent Measurements
1
2015
57
0.030
Why?
Cell Nucleus
1
1997
573
0.030
Why?
DNA Repair
1
1997
352
0.030
Why?
Laryngeal Neoplasms
1
1995
89
0.030
Why?
Radiotherapy Planning, Computer-Assisted
1
1996
192
0.030
Why?
Mice, Inbred NOD
1
2015
181
0.030
Why?
Algorithms
1
2003
1803
0.030
Why?
Mice, SCID
1
2015
237
0.030
Why?
Likelihood Functions
1
1995
253
0.030
Why?
Proportional Hazards Models
1
1996
852
0.030
Why?
Research Design
2
2003
581
0.030
Why?
Tumor Burden
1
2015
278
0.030
Why?
Neoplasms, Experimental
1
1995
270
0.030
Why?
Socioeconomic Factors
1
1996
550
0.030
Why?
Social Values
1
1994
44
0.030
Why?
Regression Analysis
1
1995
596
0.030
Why?
Diffusion of Innovation
1
1994
71
0.030
Why?
Receptors, Estrogen
1
1995
376
0.030
Why?
Genetic Diseases, Inborn
1
1994
100
0.030
Why?
Health Care Costs
1
1995
230
0.030
Why?
Patient-Centered Care
1
1995
197
0.030
Why?
Imaging, Three-Dimensional
1
2016
568
0.030
Why?
Forecasting
1
1994
309
0.030
Why?
Molecular Targeted Therapy
1
2014
264
0.030
Why?
Adenoviridae
2
2004
344
0.030
Why?
Social Change
1
1991
7
0.030
Why?
England
1
1991
42
0.030
Why?
Acquired Immunodeficiency Syndrome
1
1991
77
0.030
Why?
Maximum Tolerated Dose
1
2011
270
0.030
Why?
Cluster Analysis
1
2011
362
0.020
Why?
Costs and Cost Analysis
1
1991
150
0.020
Why?
Databases, Genetic
1
2011
255
0.020
Why?
Precision Medicine
1
2014
378
0.020
Why?
Promoter Regions, Genetic
2
2004
922
0.020
Why?
Carcinoma, Squamous Cell
1
1996
1065
0.020
Why?
Receptors, Tumor Necrosis Factor, Type II
1
2008
20
0.020
Why?
Etanercept
1
2008
32
0.020
Why?
Esophageal Neoplasms
2
2002
316
0.020
Why?
Receptors, Tumor Necrosis Factor, Type I
1
2008
43
0.020
Why?
Receptors, Tumor Necrosis Factor
1
2008
87
0.020
Why?
Health Knowledge, Attitudes, Practice
1
1993
504
0.020
Why?
Rats
2
2004
3941
0.020
Why?
Double-Blind Method
1
1991
1797
0.020
Why?
Delivery of Health Care
1
1991
374
0.020
Why?
Immunoglobulin G
1
2008
447
0.020
Why?
Retrospective Studies
1
2000
8061
0.020
Why?
Gene Expression Regulation, Neoplastic
1
2011
1181
0.020
Why?
Endothelial Cells
1
2008
404
0.020
Why?
Necrosis
2
1996
191
0.020
Why?
Reproducibility of Results
1
2011
2652
0.020
Why?
Pleural Effusion
1
2004
44
0.020
Why?
Organoplatinum Compounds
1
2004
94
0.020
Why?
Acetylcysteine
1
2004
69
0.020
Why?
Recombinant Fusion Proteins
2
1996
550
0.020
Why?
Biopsy, Needle
1
2004
231
0.020
Why?
Genes, erbB-2
1
2003
24
0.010
Why?
Probability
1
2004
351
0.010
Why?
Immunosuppressive Agents
1
2008
967
0.010
Why?
Selective Estrogen Receptor Modulators
1
2003
31
0.010
Why?
Mice, Inbred C57BL
2
2000
3025
0.010
Why?
Receptors, Steroid
1
2003
42
0.010
Why?
Paclitaxel
1
2004
458
0.010
Why?
DNA, Complementary
1
2002
391
0.010
Why?
Up-Regulation
1
2004
698
0.010
Why?
Phytotherapy
1
2003
132
0.010
Why?
Isocoumarins
1
2000
7
0.010
Why?
Umbilical Veins
1
2000
45
0.010
Why?
Drug Resistance, Neoplasm
1
2004
580
0.010
Why?
Laminin
1
2000
81
0.010
Why?
ROC Curve
1
2003
743
0.010
Why?
Drug Combinations
1
2000
218
0.010
Why?
Proteoglycans
1
2000
118
0.010
Why?
Mass Screening
1
2004
609
0.010
Why?
Collagen
1
2000
266
0.010
Why?
Angiostatins
1
1998
16
0.010
Why?
Cytokines
1
2003
754
0.010
Why?
Endothelium, Vascular
1
2000
429
0.010
Why?
Colonic Neoplasms
1
2002
550
0.010
Why?
Cohort Studies
1
2004
2703
0.010
Why?
Cell Movement
1
2000
737
0.010
Why?
Biomarkers
1
2003
1654
0.010
Why?
Dose-Response Relationship, Drug
1
2000
1948
0.010
Why?
Mastadenovirus
1
1995
4
0.010
Why?
Liposomes
1
1995
92
0.010
Why?
Cells, Cultured
1
2000
2763
0.010
Why?
Neoplasms, Radiation-Induced
1
1995
108
0.010
Why?
Radiation Tolerance
1
1995
168
0.010
Why?
Transplantation, Heterologous
1
1995
349
0.010
Why?
Thrombosis
1
1996
284
0.010
Why?
Signal Transduction
1
2003
3179
0.010
Why?
Hellman's Networks
Click the
Explore
buttons for more information and interactive visualizations!
Concepts (303)
Explore
_
Co-Authors (26)
Explore
_
Similar People (60)
Explore
_
Same Department Expand Description
Explore
_
Physical Neighbors
_